The Latest Breaking News from BLUE

Bluebird Bio Inc (NASDAQ:BLUE) is laying off about 30% of its workforce before the FDA decides the fate of two of its gene therapies. The gene therapy-focused company is showing the exit to nearly one-third of its staff to extend its cash runway into the first half of 2023 and save $160 million…

Papa John's International Inc (NASDAQ:PZZA) has re-franchised its majority stake in a joint venture between Papa Johns and Blue and Silver Ventures Ltd. The financial terms of the transaction were not disclosed. Sun Holdings, one of Papa Johns largest domestic franchise partners, has assumed control of 90 Papa Johns restaurants in Texas. Blue…

ST. LOUIS — There are a lot of ways for a team to get a win in the face of a prolonged series of losses and subpar play, and the simplest is the road the Blues took on Monday: Have a goalie play a great game.

Your morning Everton headlines as Morgan Feeney gives an exclusive interview to the ECHO and Fabian Delph hands Frank Lampard a fitness boost

According to Benzinga Pro data, during Q4, bluebird bio (NASDAQ:BLUE) posted sales of $1.61 million. Earnings were up 28.49%, but bluebird bio still reported an overall loss of $155.05 million.

Within the last quarter, bluebird bio (NASDAQ:BLUE) has observed the following analyst ratings:

Hit by several delays for its gene therapy programs, Bluebird bio Inc (NASDAQ: BLUE) ended 2021 with a cash and equivalents balance of 

The 

And, no, we're not counting *NSYNC.